Enfortumab Vedotin Plus Pembrolizumab vs. Chemotherapy for Untreated la/mUC: EV-302 Study Update ASCO GU 3 Mins Read Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At…
Durvalumab / Imfinzi Defies Expectations in MIBC, Offering Survival Gains Beyond Complete Response in NIAGARA Trial – ASCO GU 2025 ASCO GU 3 Mins Read Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer…
